Skip to content
sellWeak cluster of 510b5-1 plan

Joseph Shulman sold $620k of RYTM

Chief Technical Officer at RHYTHM PHARMACEUTICALS, INC.. 7,969 shares at an average of $77.78, traded Jul 9, 2025, filed Jul 11, 2025.

Warning score
25
Value
$620k
7,969 shares
Holdings after
8,509
-48% from before
From 52-week low
+90%
low $46.95, close $89.00
From 52-week high
0%
high $89.00, as of Jul 9, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $620k at market
    +20
  • Share of holdings sold
    Sold 48% of holdings
    +10
  • Cluster
    5 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

RYTMOct 9, 2026 · close 90.78
Since filing Jul 11, 2025: +4.7%SPY +26.5% · excess -21.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001104659-25-067430, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jul 9, 2025MOption exercise
Common Stock10b5-1
+7,969$6.80$54k16,478Jul 11, 2025
Jul 9, 2025SOpen-market sale
Common Stock10b5-1
-3,984$75.56$301k12,494Jul 11, 2025
Jul 9, 2025SOpen-market sale
Common Stock10b5-1
-3,985$80.00$319k8,509Jul 11, 2025
Jul 9, 2025MOption exercise
Stock Options (Right to Buy)derivative10b5-1
-7,969$0.00$011,953Jul 11, 2025

Related signals

Other insiders at RHYTHM PHARMACEUTICALS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
28Weak
RYTMsell 210b5-1
RHYTHM PHARMACEUTICALS, INC.
David P Meeker
President and CEO
$5.1M
50,000 shares
-17%
30Weak
RYTMsell 210b5-1
RHYTHM PHARMACEUTICALS, INC.
Hunter C Smith
Chief Financial Officer
$6.6M
62,774 shares
-36%
0Weak
RYTMsell10b5-1
RHYTHM PHARMACEUTICALS, INC.
Pamela J. Cramer
Chief Human Resources Officer
$372k
3,350 shares
-14%
0Weak
RYTMsell10b5-1
RHYTHM PHARMACEUTICALS, INC.
Pamela J. Cramer
Chief Human Resources Officer
$352k
3,350 shares
-14%
33Weak
RYTMsell 210b5-1
RHYTHM PHARMACEUTICALS, INC.
Pamela J. Cramer
Chief Human Resources Officer
$2.3M
22,866 shares
-57%
33Weak
RYTMsell 210b5-1
RHYTHM PHARMACEUTICALS, INC.
Joseph Shulman
Chief Technical Officer
$1.1M
9,748 shares
-53%
7Weak
RYTMsell 210b5-1
RHYTHM PHARMACEUTICALS, INC.
Joseph Shulman
Chief Technical Officer
$324k
2,815 shares
-25%
25Weak
RYTMsell10b5-1
RHYTHM PHARMACEUTICALS, INC.
Joseph Shulman
Chief Technical Officer
$1.6M
14,437 shares
-63%
25Weak
RYTMsell10b5-1
RHYTHM PHARMACEUTICALS, INC.
Joseph Shulman
Chief Technical Officer
$1.8M
16,781 shares
-66%
21Weak
RYTMsell 310b5-1
RHYTHM PHARMACEUTICALS, INC.
Joseph Shulman
Chief Technical Officer
$419k
4,188 shares
-33%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Joseph Shulman sold $620k of RYTM | InsiderTell